GUANABENZ ACETATE

GUANABENZ ACETATE
  • CAS No.:23256-50-0
Other grades of this product :
GUANABENZ ACETATE Basic information
Product Name:GUANABENZ ACETATE
Synonyms:Guanabenz Acetate, ≥98%;Guanabenz Acetate - CAS 23256-50-0 - Calbiochem;((2,6-dichlorobenzylidene)amino)-guanidinmonoacetate;2-((2,6-dichlorophenyl)methylene)-hydrazinecarboximidamidmonoacetate;br750;WY-8678;[2,6-DICHLOROBENZYLIDENE)-AMINO]GUANIDINE;[(2,6-DICHLOROBENZYLIDENE)AMINO]GUANIDINE ACETATE
CAS:23256-50-0
MF:C10H12Cl2N4O2
MW:291.13
EINECS:245-534-7
Product Categories:Inhibitors;WYTENSIN
Mol File:23256-50-0.mol
GUANABENZ ACETATE Chemical Properties
Melting point 227-229℃ (decomposition)
storage temp. Keep in dark place,Inert atmosphere,Room temperature
solubility H2O: 11 mg/mL
form solid
color white
Merck 14,4558
Safety Information
Hazard Codes Xn
Risk Statements 22
Safety Statements 22-36/37/39-45
RIDADR UN 2811 6.1/PG 3
WGK Germany 3
RTECS MF0382000
HazardClass 6.1(b)
PackingGroup III
HS Code 2928002500
Hazardous Substances Data23256-50-0(Hazardous Substances Data)
MSDS Information
ProviderLanguage
SigmaAldrich English
GUANABENZ ACETATE Usage And Synthesis
Usesantihypertensive
Usesα2-adrenergic agonist and IGRS selective ligand
Brand nameWytensin (Wyeth).
General DescriptionGuanabenz acetate, [(2,6-dichlorobenzylidene)amino]guanidine monoacetate (Wytensin), is acentral 2-adrenergic agonist that reduces the release of norepinephrinefrom the neuron when stimulated. The effect ofthe drug results in decreased sympathetic tone in the heart,kidneys, and peripheral blood vessels. The drug does not produceorthostatic hypotension.
Biological Activityα 2 -adrenergic agonist and IGRS (imidazoline I 2 binding site) selective ligand.
Biochem/physiol ActionsCentrally acting α2 adrenoceptor agonist; I2 imidazoline binding site ligand; antihypertensive.
PharmacokineticsThe oral bioavailability of guanabenz is 70 to 80%. Following an oral dose, the hypotensive effect of guanabenz begins within 1 hour, peaks within 2 to 7 hours, and is diminished within 6 to 8 hours. It has an elimination half-life averaging 4 to 14 hours. The blood pressure response can persist for at least 12 hours. Following IV dosing, guanabenz is distributed into the CNS, with brain concentrations 3 to 70 times higher than concurrent plasma concentrations. Guanabenz is approximately 90% bound to plasma proteins. In patients with hepatic or renal impairment, its elimination half-life may be prolonged. Guanabenz is metabolized principally by hydroxylation to its inactive metabolite, 4-hydroxyguanabenz, which is eliminated in the urine as its glucuronide (major) and sulfate conjugates. Guanabenz and its inactive metabolites are excreted principally in urine, with approximately 70 to 80% of its oral dose excreted in urine within 24 hours and approximately 10–30% in feces via enterohepatic cycling. Approximately 40% of an oral dose of guanabenz is excreted in urine as 4-hydroxyguanabenz and its glucuronide, and less than 5% is excreted unchanged. The remainder is excreted as unidentified metabolites and their conjugates.
Clinical UseOverall, the therapeutic applications for guanabenz are similar to those of clonidine and other α2-adrenergic agonists. One advantage for guanabenz is its once-a-day dosing schedule. Guanabenz has been used in diabetic patients with hypertension without adverse effect on the control of or therapy for diabetes, and it has been effective in hypertensive patients with chronic obstructive pulmonary disease, including asthma, chronic bronchitis, or emphysema. Guanabenz has been used alone or in combination with naltrexone in the management of opiate withdrawal in patients physically dependent on opiates and undergoing detoxification. Guanabenz also has been used as an analgesic in a limited number of patients with chronic pain
Side effectsOverall, the frequency of adverse effects produced by guanabenz is similar to that produced by clonidine and the other α2-adrenergic agonists, but the incidence is lower. As with the other centrally active sympatholytics (e.g., clonidine), abrupt withdrawal of guanabenz may result in rebound hypertension, but the withdrawal syndrome symptoms appear to be less severe.
GUANABENZ ACETATE Preparation Products And Raw materials

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye